Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:953 (10 November), doi:10.1136/bmj.39388.457662.1F
| The first 150 words of the full text of this article appear below. |
Ballinger and Anggiansah's review of the management of colorectal cancer made little or no mention of important aspects of current treatment.1
They did not mention the role of laparoscopic large bowel resection for colorectal cancers, which has become increasingly widely used in the United Kingdom and abroad and is now recommended as an alternative to open surgery by the National Institute for Health and Clinical Excellence (NICE ).2 A recent study has shown that laparoscopic surgery allows rapid mobilisation of the patient, an earlier return of bowel function, lower complication rates and a much earlier discharge from hospital (4 days v 11 days).3
Secondly, liver resection, for unilobar or bilobar colorectal tumour metastases, has revolutionised treatment of the condition yet only merits one sentence. Up to 50% of patients with colorectal cancers develop liver metastases after diagnosis. Chemotherapy has been shown to extend median survival. However, without liver resection, five
W J Fawcett, consultant anaesthetist, J T Lordon, surgical research fellow, N F Quiney, consultant anaesthetist, N D Karanjia, professor of surgery, T A Rockall, professor of surgery
Departments of Anaesthesia and Surgery, Royal County Hospital, Guildford GU2 7XX
wfawcett@nhs.net